Aberrant methylation and loss of expression of O6-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma

被引:15
作者
Furonaka, O
Takeshima, Y
Awaya, H
Kushitani, K
Kohno, N
Inai, K
机构
[1] Hiroshima Univ, Grad Sch Biomed Sci, Dept Pathol, Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Minami Ku, Hiroshima 7348551, Japan
关键词
aberrant methylation; adenocarcinoma; multistep carcinogenesis; O-6-methylguanine-DNA methyltransferase (MGMT); squamous cell carcinoma;
D O I
10.1111/j.1440-1827.2005.01830.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
O-6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that protects cells against the carcinogenic effects of alkylating agents. The methylation status of the MGMT gene was investigated by methylation-specific polymerase chain reaction (PCR) and expression status was investigated by immunohistochemistry in 70 cases of pulmonary squamous cell carcinoma (pulmonary SqCC), including 23 cases of the central type and 47 cases of the peripheral type, and in 53 cases of the peripheral type of pulmonary adenocarcinoma (AC). The frequency of MGMT methylation was 36% in SqCC and 42% in AC. Cases with MGMT methylation correlated significantly with T factor in SqCC (P = 0.047) and AC (P = 0.03). In SqCC, the frequency of MGMT methylation was 26% in the central type and 40% in the peripheral type; a significant correlation was not found (P = 0.29). In AC with mixed subtypes showing MGMT methylation, the level of MGMT expression in the bronchioloalveolar carcinoma (BAC) area (non-invasive status) was significantly higher than that in the papillary or acinar AC area (invasive status; P = 0.0002). This trend was not found in AC with mixed subtypes showing no MGMT methylation (P = 0.10). These findings suggest that MGMT inactivation is an event that occurs in the late carcinogenic process in SqCC and AC, and that AC progress from non-invasive status to invasive status with MGMT inactivation induced by the promoter DNA methylation.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 41 条
[1]  
Ahrendt SA, 2000, CANCER RES, V60, P3155
[2]  
[Anonymous], 1999, WHO HISTOLOGICAL CLA
[3]  
Brabender J, 2003, CLIN CANCER RES, V9, P223
[4]  
Chan EC, 2002, CLIN CANCER RES, V8, P3741
[5]  
COSTELLO JF, 1994, J BIOL CHEM, V269, P17228
[6]   GENETIC STUDIES OF LAC REPRESSOR .4. MUTAGENIC SPECIFICITY IN LACI GENE OF ESCHERICHIA-COLI [J].
COULONDRE, C ;
MILLER, JH .
JOURNAL OF MOLECULAR BIOLOGY, 1977, 117 (03) :577-606
[7]   Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers [J].
Divine, KK ;
Pulling, LC ;
Marron-Terada, PG ;
Liechty, KC ;
Kang, T ;
Schwartz, AG ;
Bocklage, TJ ;
Coons, TA ;
Gilliland, FD ;
Belinsky, SA .
INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (03) :400-405
[8]   Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours [J].
Esteller, M ;
Herman, JG .
JOURNAL OF PATHOLOGY, 2002, 196 (01) :1-7
[9]  
FORNACE AJ, 1990, CANCER RES, V50, P7908
[10]  
GARDAR AF, 1999, J NATL CANCER I, V91, P299